hotspot -WSS

hotspot

author：fashion 2025-10-02 22:56:26 - browse：2

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: BridgeBio, Akero, and human embryo models

WSS

First over

Florida health officials providing scant details on measles cases

Ozempic has benefits for kidney disease as well as diabetes

Has Bernie Sanders reached the limit of his pharma bullying effort?

For AI in health care standards, federal regulators join with industry group

Microsoft's Peter Lee: Generative AI could help doctors be more human

explore

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

He's 19 months old and has one of the world’s rarest diseases

The high cost of giving birth even with insurance

Most antidepressants don't work on kids, teens, study finds

Medicare details structure of new drug price negotiation program

Streamlined flu vaccines recommended by FDA advisory panel

Apple is now the first public company to be valued at $3 trillion

Most antidepressants don't work on kids, teens, study finds

United colonoscopy coverage change 'may cost lives,' doctors say

PBM executives asked to testify by House panel

hotspot

Most antidepressants don't work on kids, teens, study finds

AltruBio raises $225 million to develop ulcerative colitis drug

First over

Welsh Carson private equity firm escapes from FTC antitrust case

As billionaires fund anti

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

focus

hotspot

leisure time

knowledge